Navigation Links
Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
Date:3/4/2009

100% Technical Success, No Peri-procedural Complications Reported With Coronary Device

DOYLESTOWN, Pa., March 4 /PRNewswire/ -- Prescient Medical, Inc. reached a crucial milestone in February by completing the enrollment of 30 patients in the first phase of its first-in-human clinical trial for the vProtect(TM) Luminal Shield, conducted at the Corbic Research Institute in Colombia. The Shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural or in-hospital complications were reported for any of the patients. The patients enrolled in the study had non-calcified lesions in coronary arteries, lesions that would normally be treated with traditional balloon-expandable stents.

No major adverse coronary events (MACE) were reported at 30 days post-implant in the 28 patients who had reached that milestone. Nine-month angiographic follow-up was reported for 2 initial patients; there was no evidence of significant neointimal growth in these patients. "We are very pleased with the performance of the Shield in this preliminary study. We have achieved an excellent technical result, and soon we will know more about clinical outcomes with the Shield," said co-principal investigator Juan A. Delgado, MD of Corbic Research Institute.

Prescient Medical has also broken new ground with a study evaluating use of the vProtect(TM) Luminal Shield in non-obstructive "vulnerable plaque" lesions that may rupture and cause acute myocardial infarction. According to Dr. Delgado, "The self-expanding Shield is designed to deploy with less injury to the artery, which should reduce neointimal overgrowth compared with currently marketed bare metal stents. We think these properties make the Shield a promising treatment to stabilize vulnerable plaque and prevent major events like heart attacks."

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at www.prescientmedical.com or call +1-866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
4. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
5. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
6. Foreign Medical Devices are in High Demand in Russia
7. Oridion Announces Significant Medical Studies Presented at STA
8. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
9. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
10. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
11. ProUroCare Medical Inc. Announces Pricing of Equity Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Attending college is ... those with type 1 diabetes, the journey can be ... schedules, assignments and campus activities, they also manage the ... top of that, many are living away from home ... (Foundation) Lilly Diabetes Tomorrow,s Leaders Scholarship with $100,000 ...
(Date:2/11/2016)... , Feb. 11, 2016 Brain Cancer ... new treatment method at West Cancer Center . ... electric fields to inhibit cancer cell replication causing death ... more than a decade to show a significant extension ... Multiforme (GBM) patients. Currently, West Cancer Center is the ...
(Date:2/11/2016)... 2016  AbbVie, a global biopharmaceutical company, announced ... to provide financial support for exceptional students living ... education goals. Fifteen scholars will be selected to ... The AbbVie Rheumatology Scholarship is currently accepting applications. ... corporate social responsibility, brand and communications, AbbVie. "By ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 2016 , ... The president released a FY 2017 budget request on Tuesday ... of the cost burden to military beneficiaries. , MOAA’s president, retired Air Force ... as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative ... gearing up for their simultaneous grand openings in March. All seven practices are ... you’re probably wondering, is reversing diabetes possible? According to this 2011 CNN article ...
(Date:2/11/2016)... ... 2016 , ... Thermi™, a world leader in thermistor-regulated energy ... promotions of Allison Kelly to executive vice president of the company’s new North ... North American capital sales, and Wendy Oseas to vice president of global marketing. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. ... Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. and ... Intel on value-based health benefits program Connected Care, will discuss the challenges they ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for Case Manager ... of Commissioners. Individuals interested in volunteer board service are encouraged to apply. The ... settings and across allied health to contribute to its mission and vision. The ...
Breaking Medicine News(10 mins):